{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:51:00Z","timestamp":1775245860479,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000263","name":"Parkinson Society Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000263","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Brain Res"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00221-018-5390-4","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T04:24:30Z","timestamp":1538972670000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat"],"prefix":"10.1007","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6779-8713","authenticated-orcid":false,"given":"Imane","family":"Frouni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Belliveau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9lodie","family":"Bourgeois-Cayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fleur","family":"Gaudette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Beaudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9869-6752","authenticated-orcid":false,"given":"Adjia","family":"Hamadjida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"5390_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0006-8993(94)91511-3","volume":"667","author":"R Arai","year":"1994","unstructured":"Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenousl-DOPA in the rat, with reference to the involvement of aromaticl-amino acid decarboxylase. Brain Res 667:295\u2013299","journal-title":"Brain Res"},{"key":"5390_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0304-3940(95)11817-G","volume":"195","author":"R Arai","year":"1995","unstructured":"Arai R, Karasawa N, Geffard M, Nagatsu I (1995) l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 195:195\u2013198","journal-title":"Neurosci Lett"},{"key":"5390_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0014-2999(03)01992-7","volume":"473","author":"GD Bartoszyk","year":"2003","unstructured":"Bartoszyk GD, van Amsterdam C, Bottcher H, Seyfried CA (2003) EMD 281014, a new selective serotonin 5-HT2A receptor antagonist. Eur J Pharmacol 473:229\u2013230","journal-title":"Eur J Pharmacol"},{"key":"5390_CR4","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/jnr.21978","volume":"87","author":"C Bishop","year":"2009","unstructured":"Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD (2009) Contribution of the striatum to the effects of 5-HT1A receptor stimulation in l-DOPA-treated hemiparkinsonian rats. J Neurosci Res 87:1645\u20131658. https:\/\/doi.org\/10.1002\/jnr.21978","journal-title":"J Neurosci Res"},{"key":"5390_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/bmj.312.7033.770","volume":"312","author":"JM Bland","year":"1996","unstructured":"Bland JM, Altman DG (1996) Transforming data. Bmj 312:770","journal-title":"Bmj"},{"key":"5390_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396. https:\/\/doi.org\/10.1016\/0893-133X(94)00129-N","journal-title":"Neuropsychopharmacology"},{"key":"5390_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bj\u00f6rklund A (2007) Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819\u20131833","journal-title":"Brain"},{"key":"5390_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/0471142301.ns0925s41","volume":"41","author":"MA Cenci","year":"2007","unstructured":"Cenci MA, Lundblad M (2007) Ratings of l-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson\u2019s disease in rats and mice. Curr Protoc Neurosci 41:1\u201323","journal-title":"Curr Protoc Neurosci"},{"key":"5390_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S0165-0173(00)00039-4","volume":"34","author":"F Cicchetti","year":"2000","unstructured":"Cicchetti F, Prensa L, Wu Y, Parent A (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington\u2019s disease. Brain Res Brain Res Rev 34:80\u2013101","journal-title":"Brain Res Brain Res Rev"},{"key":"5390_CR10","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS et al (2014) The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain 137:2731\u20132742. https:\/\/doi.org\/10.1093\/brain\/awu195","journal-title":"Brain"},{"key":"5390_CR11","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670\u20131683","journal-title":"JAMA"},{"key":"5390_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","volume":"62","author":"F Durif","year":"2004","unstructured":"Durif F, Debilly B, Galitzky M et al (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62:381\u2013388","journal-title":"Neurology"},{"key":"5390_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jchromb.2017.07.007","volume":"1061\u20131062","author":"F Gaudette","year":"2017","unstructured":"Gaudette F, Hamadjida A, B\u00e9dard D, Nuara SG, Beaudry F, Huot P (2017) Development and validation of a high-performance liquid chromatography\u2013tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasma. J Chromatogr B 1061\u20131062:392\u2013398. https:\/\/doi.org\/10.1016\/j.jchromb.2017.07.007","journal-title":"J Chromatogr B"},{"key":"5390_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchromb.2018.06.036","volume":"1093\u20131094","author":"F Gaudette","year":"2018","unstructured":"Gaudette F, Hamadjida A, Bedard D et al (2018) Development of a selective and sensitive high-performance liquid chromatography\u2013tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset. J Chromatogr B Analyt Technol Biomed Life Sci 1093\u20131094:1\u20137. https:\/\/doi.org\/10.1016\/j.jchromb.2018.06.036","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"5390_CR15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mds.21897","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Laska E, Hicking C et al (2008) Placebo influences on dyskinesia in Parkinson\u2019s disease. Mov Disord 23:700\u2013707. https:\/\/doi.org\/10.1002\/mds.21897","journal-title":"Mov Disord"},{"key":"5390_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuropharm.2018.06.038","volume":"139","author":"A Hamadjida","year":"2018","unstructured":"Hamadjida A, Nuara SG, Bedard D, Gaudette F, Beaudry F, Gourdon JC, Huot P (2018) The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset. Neuropharmacology 139:61\u201367. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.06.038","journal-title":"Neuropharmacology"},{"key":"5390_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney multicenter study of Parkinson\u2019s disease: non-l-DOPA-responsive problems dominate at 15 years. Mov Disord 20:190\u2013199. https:\/\/doi.org\/10.1002\/mds.20324","journal-title":"Mov Disord"},{"key":"5390_CR18","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1016\/j.bmc.2009.03.021","volume":"17","author":"MM Herth","year":"2009","unstructured":"Herth MM, Kramer V, Piel M, Palner M, Riss PJ, Knudsen GM, Rosch F (2009) Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem 17:2989\u20133002. https:\/\/doi.org\/10.1016\/j.bmc.2009.03.021","journal-title":"Bioorg Med Chem"},{"key":"5390_CR19","volume-title":"Statistical methods for psychology","author":"DC Howell","year":"2006","unstructured":"Howell DC (2006) Statistical methods for psychology, 6th edn. Wadsworth Publishing, Belmont","edition":"6"},{"key":"5390_CR20","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","volume":"31","author":"P Huot","year":"2011","unstructured":"Huot P, Johnston TH, Lewis KD et al (2011) Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. J Neurosci 31:7190\u20137198. https:\/\/doi.org\/10.1523\/JNEUROSCI.1171-11.2011","journal-title":"J Neurosci"},{"key":"5390_CR21","first-page":"194.e195","volume":"33","author":"P Huot","year":"2012","unstructured":"Huot P, Johnston TH, Winkelmolen L, Fox SH, Brotchie JM (2012a) 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with l-DOPA. Neurobiol Aging 33:194.e195\u2013194.e115","journal-title":"Neurobiol Aging"},{"key":"5390_CR22","doi-asserted-by":"publisher","first-page":"194 e195","DOI":"10.1016\/j.neurobiolaging.2010.04.035","volume":"33","author":"P Huot","year":"2012","unstructured":"Huot P, Johnston TH, Winkelmolen L, Fox SH, Brotchie JM (2012b) 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with l-DOPA. Neurobiol Aging 33:194 e195\u2013194 e115. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.04.035","journal-title":"Neurobiol Aging"},{"key":"5390_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/FBP.0000000000000096","volume":"26","author":"P Huot","year":"2015","unstructured":"Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM (2015) l-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. Behav Pharmacol 26:101\u2013108. https:\/\/doi.org\/10.1097\/FBP.0000000000000096","journal-title":"Behav Pharmacol"},{"key":"5390_CR24","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1124\/jpet.106.110429","volume":"319","author":"MM Iravani","year":"2006","unstructured":"Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P (2006) In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 319:1225\u20131234. https:\/\/doi.org\/10.1124\/jpet.106.110429","journal-title":"J Pharmacol Exp Ther"},{"key":"5390_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner P (2008) Molecular mechanisms of l-DOPA-induced dyskinesia. Nat Rev Neurosci 9:665\u2013677. https:\/\/doi.org\/10.1038\/nrn2471","journal-title":"Nat Rev Neurosci"},{"key":"5390_CR26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0026-895X(25)12558-3","volume":"27","author":"JE Leysen","year":"1985","unstructured":"Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27:600\u2013611","journal-title":"Mol Pharmacol"},{"key":"5390_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/syn.20722","volume":"64","author":"Y Li","year":"2010","unstructured":"Li Y, Huang XF, Deng C et al (2010) Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats. Synapse 64:224\u2013230. https:\/\/doi.org\/10.1002\/syn.20722","journal-title":"Synapse"},{"key":"5390_CR28","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/00002826-198610000-00010","volume":"9","author":"A Maertens de Noordhout","year":"1986","unstructured":"Maertens de Noordhout A, Delwaide PJ (1986) Open pilot trial of ritanserin in parkinsonism. Clin Neuropharmacol 9:480\u2013484","journal-title":"Clin Neuropharmacol"},{"key":"5390_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00213-004-1817-7","volume":"175","author":"D Mamo","year":"2004","unstructured":"Mamo D, Sedman E, Tillner J, Sellers EM, Romach MK, Kapur S (2004) EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. Psychopharmacology 175:382\u2013388. https:\/\/doi.org\/10.1007\/s00213-004-1817-7","journal-title":"Psychopharmacology"},{"key":"5390_CR30","first-page":"262","volume":"43","author":"G Meco","year":"1988","unstructured":"Meco G, Marini S, Linfante I, Modarelli F, Agnoli A (1988) Controlled single-blind crossover study of ritanserin and placebo in l-DOPA-induced dyskinesias in Parkinson\u2019s disease. Curr Ther Res 43:262\u2013270","journal-title":"Curr Ther Res"},{"key":"5390_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","volume":"38","author":"S Navailles","year":"2010","unstructured":"Navailles S, Bioulac B, Gross C, De Deurwaerd\u00e8re P (2010) Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson\u2019s disease. Neurobiol Dis 38:136\u2013143","journal-title":"Neurobiol Dis"},{"key":"5390_CR32","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","volume":"152","author":"AL Nordstrom","year":"1995","unstructured":"Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444\u20131449","journal-title":"Am J Psychiatry"},{"key":"5390_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0169-328X(95)00004-C","volume":"29","author":"S Numan","year":"1995","unstructured":"Numan S, Lundgren KH, Wright DE, Herman JP, Seroogy KB (1995) Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res Mol Brain Res 29:391\u2013396","journal-title":"Brain Res Mol Brain Res"},{"key":"5390_CR34","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1093\/brain\/awr165","volume":"134","author":"KE Ohlin","year":"2011","unstructured":"Ohlin KE, Francardo V, Lindgren HS et al (2011) Vascular endothelial growth factor is upregulated by l-DOPA in the parkinsonian brain: implications for the development of dyskinesia. Brain 134:2339\u20132357. https:\/\/doi.org\/10.1093\/brain\/awr165","journal-title":"Brain"},{"key":"5390_CR35","volume-title":"The rat brain in stereotaxic coordinates: compact","author":"G Paxinos","year":"2017","unstructured":"Paxinos G, Watson C (2017) The rat brain in stereotaxic coordinates: compact. Academic Press, New York"},{"key":"5390_CR36","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"PD Med Collaborative Group","year":"2014","unstructured":"PD Med Collaborative Group (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384:1196\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(14)60683-8","journal-title":"Lancet"},{"key":"5390_CR37","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484\u20131491","journal-title":"N Engl J Med"},{"key":"5390_CR38","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1111\/j.1460-9568.2011.07675.x","volume":"33","author":"G Riahi","year":"2011","unstructured":"Riahi G, Morissette M, Parent M, Di Paolo T (2011) Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. Eur J Neurosci 33:1823\u20131831. https:\/\/doi.org\/10.1111\/j.1460-9568.2011.07675.x","journal-title":"Eur J Neurosci"},{"key":"5390_CR39","volume-title":"Clinical pharmacokinetics: concepts and application","author":"M Rowland","year":"1995","unstructured":"Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and application. Lippincott Williams and Wilkins., Philadelphia"},{"key":"5390_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","volume":"39","author":"T Schallert","year":"2000","unstructured":"Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39:777\u2013787","journal-title":"Neuropharmacology"},{"key":"5390_CR41","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.neuropharm.2005.12.004","volume":"50","author":"JL Taylor","year":"2006","unstructured":"Taylor JL, Bishop C, Ullrich T, Rice KC, Walker PD (2006) Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology 50:761\u2013768. https:\/\/doi.org\/10.1016\/j.neuropharm.2005.12.004","journal-title":"Neuropharmacology"},{"key":"5390_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","volume":"5","author":"U Ungerstedt","year":"1968","unstructured":"Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107\u2013110","journal-title":"Eur J Pharmacol"},{"key":"5390_CR43","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","volume":"90","author":"KE Vanover","year":"2008","unstructured":"Vanover KE, Betz AJ, Weber SM et al (2008) A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav 90:540\u2013544. https:\/\/doi.org\/10.1016\/j.pbb.2008.04.010","journal-title":"Pharmacol Biochem Behav"},{"key":"5390_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.physbeh.2007.05.033","volume":"92","author":"X Zhang","year":"2007","unstructured":"Zhang X, Andren PE, Svenningsson P (2007) Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson\u2019s disease model. Physiol Behav 92:29\u201333. https:\/\/doi.org\/10.1016\/j.physbeh.2007.05.033","journal-title":"Physiol Behav"},{"key":"5390_CR45","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S (2010) PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Progr Biomed 99:306\u2013314. https:\/\/doi.org\/10.1016\/j.cmpb.2010.01.007","journal-title":"Comput Methods Progr Biomed"}],"container-title":["Experimental Brain Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00221-018-5390-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00221-018-5390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00221-018-5390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:52:53Z","timestamp":1775242373000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00221-018-5390-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["5390"],"URL":"https:\/\/doi.org\/10.1007\/s00221-018-5390-4","relation":{},"ISSN":["0014-4819","1432-1106"],"issn-type":[{"value":"0014-4819","type":"print"},{"value":"1432-1106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"29 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There are no conflicts of interest. PH has received speaker and travel fees from UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}